<a href="https://www.fiercebiotech.com/biotech/asco-2026-paradigm-shift-rare-gut-cancer-looms" hreflang="en">At ASCO 2026, a ‘paradigm shift’ for a rare gut cancer looms</a>
At ASCO 2026, GSK introduced velzatinib, a new tyrosine kinase inhibitor aimed at treating gastrointestinal stromal tumors (GISTs), which could potentially redefine standard care by effectively targeting both primary and secondary mutations in the c-KIT enzyme. Preliminary results showed promising tumor shrinkage rates in patients, positioning velzatinib as a potential improvement over existing treatments like Gleevec and Sutent.
GSK's development of velzatinib, a precision medicine targeting multiple KIT mutations, represents a potential paradigm shift in the treatment of gastrointestinal stromal tumors (GISTs). With its promising phase 1 trial results showing significant tumor shrinkage and a better side effect profile compared to existing therapies like Sutent, velzatinib could redefine the standard of care if successful in upcoming phase 3 trials. This advancement signals a significant investment opportunity in precision oncology, particularly in therapies targeting specific genetic mutations.